The woodchuck hepatitis virus (WHV) and its natural host, the Eastern woodchuck (MarmotaOf several virus/host animal models for chronic hepatitis B virus (HBV) infection in humans, the woodchuck hepatitis virus (WHV) and its natural host, the Eastern Woodchuck (Marmota monax), constitute a useful model of HBV-induced disease, including hepatocellular carcinoma. 1,2 Several published studies have used the WHV/woodchuck system to investigate potential antiviral therapies for chronic HBV infection. [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] However, these studies primarily focused on experimental new therapies that have not been used in clinical studies, and few have sought to demonstrate that antiviral therapy of chronic WHV infection in woodchucks is generally predictive of therapy with the same agents in humans. To date, there has not been a comprehensive report of the effects of many of the antiviral agents used in human clinical studies in the WHV/woodchuck experimental animal model system, which makes it difficult to gauge the potential benefit of new experimental treatments in humans.In this report, we compared the relative effectiveness of 5 clinically relevant antiviral agents used against chronic HBV infection in clinical trials on WHV replication in chronically infected woodchucks in a series of placebo-controlled trials conducted between 1990 and 1995. The antiviral agents were administered at doses that were calculated to be the approximate metabolic equivalent of the doses used in humans. Because the levels of the serological and hepatic markers of WHV replication in all the placebo-treated groups were highly consistent and not statistically different, it is possible to make valid comparisons between the relative effectiveness of the various compounds against WHV replication. We show here that the relative antiviral activity and toxicity profiles of the various agents used in chronic WHV carrier woodchucks were very similar to that observed in clinical studies for the treatment of chronic HBV infection. These studies demonstrate that treatment of chronic WHV infection in woodchucks is highly predictive of analogous therapies for chronic HBV infection and establish a basis for the comparison of the relative antiviral activities of future experimental therapies in this important experimental animal model.
MATERIALS AND METHODSWoodchucks. The woodchucks used in these studies were born to WHV-negative females in a breeding colony maintained at Cornell University. Animals were inoculated at 3 days of age with 5 million woodchuck infectious doses of a standardized WHV inoculum pool Abbreviations: HBV, hepatitis B virus; WHV, woodchuck hepatitis virus; Ara-AMP, adenine-5Ј-arabinoside monophosphate; AZT, 3Ј azido-3Ј-deoxythymidine; 3TC, (Ϫ)-L-2Ј,3Ј-dideoxy-3Ј-thiacytidine; PCR, polymerase chain reaction; WHsAg, woodchuck hepatitis surface antigen; anti-WHs, woodchuck hepatitis surface antigen antibody; anti-WHc, woodchuck hepatitis core antigen antibody; RI, replication intermediate; A...